Lithuanian researchers are exploring alternative methods to traditional injectable vaccines, raising discussions about vaccine accessibility and production challenges.
Recent research by Lithuanian scientists has opened a dialogue around new biotechnologies and the future of vaccination. This inquiry seeks alternatives to traditional injectable vaccines, highlighting issues surrounding accessibility even when effective vaccines exist. VU GMC doctoral student Emilija VasiliΕ«naitΔ points to various factors contributing to these challenges, including complex manufacturing processes and logistical hurdles.
The COVID-19 pandemic has exacerbated these concerns, revealing that despite the rapid development of mRNA vaccine technology, distribution faced severe challenges, particularly due to the need for ultra-cold storage conditions in many regions. These logistical issues have made it difficult to ensure widespread vaccine availability, especially in underserved areas where access to such conditions is limited.
Additionally, a noticeable trend indicates decreasing vaccination rates in many countries, even as data on the safety and efficacy of injectable vaccines accumulates. The lack of significant changes in these rates prompts further examination into the existing vaccination frameworks and the ways they can be improved to ensure better public health outcomes.
